Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer

Publication date: Available online 31 March 2018
Source:Actas Urológicas Españolas (English Edition)

Author(s): M. Unda-Urzaiz, R. Sousa-Campo, A. Rodríguez-Antolín, C. Silva-Marins, A. Juárez-Soto, B. Miñana-López, A. Figueiredo-de Castro, J.M. Cozar-Olmos

Context Radium-223 is an α-particle transmitter with specific action on bone metastases. The Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study showed that radium-223 extended overall survival and delayed the onset of bone events in patients with symptomatic castration-resistant prostate cancer with bone metastases (mCRPC) and without visceral metastases, with a good safety profile. Objective To review the new scientific evidence on radium-223 based on prespecified and post hoc analyses of the ALSYMPCA study and on early-access programs after the publication of the ALSYMPCA study, thereby providing new data on the management of patients with mCRPC. Acquisition of evidence We searched for evidence on PubMed and in the abstracts of international urology and oncology congresses, as well as ongoing clinical trials (ClinicalTrials.gov). Synthesis of the evidence The results of the reviewed studies offer promising results that will broaden the therapeutic benefits of radium-223 to patients with mild symptoms and those with no symptoms. The results also provide preliminary evidence on the benefit of radium-223 treatment after the failure of docetaxel, enzalutamide or abiraterone or the combination of radium-223 with these agents or other therapeutic agents such as bone-targeted agents and immunotherapy. Conclusion Radium-223 can be a treatment option for patients with mild symptoms and can provide a therapeutic benefit after failure of currently available treatments or in combination with these treatments. This evidence should be corroborated in clinical trials before being added to clinical practice.

Comments are closed.